Alcami recently contributed to an article in Contract Pharma titled "Oral Solids Endure & Evolve."
Contract Pharma talks with several contract service providers about the state of the oral solid dose development and manufacturing market.
The oral solid dose (OSD) development through manufacturing pipeline of products is expanding at a robust rate—even while industry watches the investment, interest and demand for biologics and biosimilars growing rapidly. There are several reasons OSDs continue to be the most popular dosage form for getting drugs to patients. In addition to being cost effective and relatively easy to make compared to their large molecule counterparts, they are most importantly, patient friendly, especially among the pediatric and geriatric populations.